

Janet T. Mills
Governor

Jeanne M. Lambrew, Ph.D.
Commissioner



Maine Department of Health and Human Services
Office of MaineCare Services - Pharmacy Unit
11 State House Station
Augusta, Maine 04333-0011
Toll Free: (866) 796-2463; TTY: Dial 711 (Maine Relay)
Fax: (207) 287-8601

DUR COMMITTEE AGENDA

Date: Tuesday, March 12, 2019
Time: 5:30PM to 8:30PM
Location: Augusta Armory, 179 Western Avenue, Augusta, ME

- 1) Call to Order
- 2) MaineCare Updates
- 3) Public Comments
- 4) Old Business
- 5) Closed Session
 - Drug Financial Information Review
- 6) New Business (open session)
 - Reviews on Biosimilars

 - Retro DUR
 - Data Presentation: Vivitrol Adherence
 - Introduction: Continuous use of antidepressants at 3, 6 and 12 months after initiation

 - New Drug Review

Abilify Mycite
Arikayce
Bryhali
Copiktra
Cequa
Daurismo
Galafold
Inventys

Lorbrena
Panzyga
Qbrexza pad
Siklos
Symjepi
Sympazan
Tiglutik
Tolsura

Xelpros
Xerava
Xospata
Xyosted
Yupelri
Zemdri

A. FDA Safety Alerts

FDA warns that symptoms of a serious condition affecting the blood cells are not being recognized with the leukemia medicine Idhifa (enasidenib)

https://www.fda.gov/Drugs/DrugSafety/ucm626923.htm?utm_campaign=New%20FDA%20Drug%20Safety%20Communication%20on%20Idhifa%20%28enasidenib%20mesylate%29-%20Drug%20I&utm_medium=email&utm_source=Eloqua

Fluoroquinolone Antibiotics: Safety Communication - Increased Risk of Ruptures or Tears in the Aorta Blood Vessel in Certain Patients

https://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm628960.htm?utm_campaign=FDA%20MedWatch%20-%20Fluoroquinolone%20Antibiotics&utm_medium=email&utm_source=Eloqua

FDA warns about rare but serious risks of stroke and blood vessel wall tears with multiple sclerosis drug Lemtrada (alemtuzumab)

https://www.fda.gov/Drugs/DrugSafety/ucm624247.htm?utm_campaign=FDA%20MedWatch%20-%20Lemtrada%20%28alemtuzumab%29%3A%20Drug%20Safety%20Communication&utm_medium=email&utm_source=Eloqua

B. Next Meeting (Tuesday, June 11, 2019 (from 5:30pm to 8:30pm))

C. Adjournment: 8:30PM